Why It Matters
The U.S. Fifth Circuit Court of Appeals is set to weigh in on a pivotal legal battle that could redefine how abortion medications are distributed across the United States. The outcome will determine whether federal agencies can mandate remote prescribing of mifepristone or if states retain the authority to require in-person medical supervision, directly impacting reproductive healthcare access and state enforcement powers.
What Happened
As first reported by floridaphoenix.com, the Fifth Circuit will hear oral arguments next week in Louisiana v. Food and Drug Administration. The case centers on a 2023 FDA regulation that permits physicians to prescribe mifepristone via telehealth without requiring patients to visit a clinic or doctor’s office in person. Louisiana contends that this federal rule undermines the Supreme Court’s 2022 decision in Dobbs v. Jackson Women’s Health Organization, which returned authority over abortion regulation to individual states.
The Biden administration originally expanded telehealth access to mifepristone during the COVID-19 pandemic, citing public health emergencies and logistical barriers. Louisiana argues that maintaining these relaxed standards after the emergency designation ended violates statutory requirements and infringes on state sovereignty regarding medical practice and abortion restrictions.
This is not the first time the Fifth Circuit has addressed this specific dispute. Earlier this year, the appellate court ruled in favor of Louisiana, granting a temporary order to reinstate in-person receipt requirements for mifepristone within the state. However, the U.S. Supreme Court subsequently blocked that ruling, allowing the federal telehealth policy to remain in effect while the broader legal challenge proceeds.
The Trump administration has requested that courts delay proceedings pending a comprehensive safety review of the drug. Three separate federal lawsuits are currently challenging telehealth access to mifepristone: one led by Louisiana in the Fifth Circuit, and others filed by Missouri and Texas in their respective jurisdictions.
By the Numbers
91,000 — abortions provided last year via telehealth prescription of abortion medication sent by mail to states with bans
9,300+ — such abortions that occurred in Louisiana last year
21 — states where Carafem operates telehealth or physical health centers
50 — U.S. states potentially affected by the case outcome
2022 — year Roe v. Wade was overturned and Dobbs decision issued
2023 — year of the contested FDA rule allowing remote prescribing
9 a.m. CDT — time oral arguments are scheduled for Wednesday
Zoom Out
The legal conflict reflects a broader national tension between federal regulatory authority and state-level abortion bans. Since the overturning of Roe v. Wade in 2022, medication abortion has become the most common form of abortion in the United States. The ability to prescribe these drugs remotely has allowed patients in restrictive states to access care from providers in states where abortion remains legal.
Two mifepristone drugmakers have intervened in the case on behalf of the FDA, arguing that restricting telehealth access could harm public health and disrupt established medical practices. Conversely, conservative legal groups view the litigation as a critical test of state enforcement capabilities post-Dobbs.
The Supreme Court previously dismissed a similar lawsuit filed by the Alliance for Hippocratic Medicine two years ago, ruling that the doctor-plaintiffs lacked standing to challenge the FDA’s approval of mifepristone. However, Louisiana’s suit proceeds on different legal grounds, focusing on state enforcement and statutory compliance rather than individual physician standing.
Melissa Grant, co-founder of Carafem, a provider operating in 21 states where abortion is legal, warned that the ruling could have widespread consequences. “What this is doing is shutting down access to people in states that have committed to continuing to make abortion legal, and it will impact people in all 50 states,” Grant told the Florida Phoenix.
Gabriella McIntyre, legal counsel for Alliance Defending Freedom, framed the case as a test of state sovereignty. “If Louisiana wins this case, we’re going to see for the first time what it looks like under an actual Dobbs regime, where pro-life states get to enforce their laws protecting the unborn,” McIntyre said.
What’s Next
Oral arguments are scheduled for 9 a.m. CDT on Wednesday and will be livestreamed through the court system. The Fifth Circuit’s decision could set a precedent for how federal drug regulations interact with state abortion bans, potentially affecting telehealth practices nationwide. If the court rules in favor of Louisiana, it may trigger further appeals to the Supreme Court, which has already signaled reluctance to intervene in procedural disputes regarding mifepristone distribution.
The resolution of this case will likely influence legislative efforts in both restrictive and permissive states, as lawmakers consider how to align state laws with federal drug policies. Additionally, the Trump administration’s request for a safety review may complicate the timeline, potentially delaying final implementation of any new restrictions until the FDA completes its assessment.